• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

    1/22/24 8:23:00 AM ET
    $DMAC
    $MRNS
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DMAC alert in real time by email

    Executive with Strong Track Record in Advancing Pipelines Through Clinical Development

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances.

    "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "She is a board-certified neurologist and recognized clinical leader in the neurology with a demonstrated track record in progressing the development of therapeutics for multiple neuroscience indications. Having worked with several early and mid-stage companies, she is very experienced in clinical research and managing drug candidates through the clinical development and regulatory process. Her experience also includes playing a key role in the acquisition of multiple biotechnology companies. We welcome Lorianne and believe her extensive expertise will benefit us tremendously as our ReMEDy 2 trial for acute ischemic stroke is now recruiting patients."

    "This is a very exciting time to join DiaMedica as it resumes enrollment in its ReMEDy2 trial," said Dr. Masuoka, "I look forward to accelerating the development of DM199 and bringing a treatment option to the large number of ischemic stroke patients who currently have no good treatment options."

    Dr. Masuoka has more than 25 years of experience building and expanding high value pipelines in the biopharmaceutical industry that have resulted in drug approvals and strategic alliances. She is a board-certified neurologist, experienced in treating stroke patients, who has successfully created and overseen high performing teams to lead the clinical development of new medicines, with a focus in neurology and oncology. Dr. Masuoka served as Chief Medical Officer of Epygenix Therapeutics, Marinus Pharmaceuticals (NASDAQ:MRNS), Cubist Pharmaceuticals ($9.5B acquisition by Merck), and Nektar Therapeutics (NASDAQ:NKTR) where, as a member of executive management, she managed teams in the areas of clinical research, pharmacovigilance, biostatistics and data management, regulatory affairs, and clinical operations. Previously, she held various roles of increasing responsibility at FivePrime Therapeutics ($1.9B acquisition by Amgen) and Chiron (now Novartis). In addition to her executive roles, Dr. Masuoka most recently served as a Board member at Pfenex Inc. ($516M acquisition by Ligand) and serves as a Board member at Opiant Pharmaceuticals (up to $500M acquisition by Indivior). Dr. Masuoka received her medical degree from the University of California, Davis, where she also completed her residency in neurology. She completed her epilepsy fellowship at Yale University and is board certified by the American Board of Psychiatry and Neurology.

    Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    In connection with Dr. Masuoka's appointment, DiaMedica granted her an inducement stock option to purchase 285,000 shares of DiaMedica's common stock pursuant to the DiaMedica Therapeutics, Inc. 2021 Employment Inducement Incentive Plan. The inducement grant was approved by the Company's compensation committee of the board of directors and was effective as of Dr. Masuoka's first date of employment, January 22, 2024, and was a material inducement to her acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of her compensation.

    About ReMEDy2 Trial

    The ReMEDy2 trial is an adaptive design, randomized, double-blind, placebo-controlled trial studying the use of the Company's product candidate, DM199, to treat acute ischemic stroke (AIS) patients. The trial is intended to enroll approximately 350 patients at up to 100 sites globally. Patients enrolled in the trial will be treated for three weeks with either DM199 or placebo, beginning within 24 hours of the onset of AIS symptoms, with the final follow-up at 90 days. The trial excludes patients treated with tissue plasminogen activator (tPA) and/or mechanical thrombectomy. DiaMedica believes that the ReMEDy2 trial has the potential to serve as a pivotal registration study of DM199 in this patient population.

    About DM199

    DM199 is a recombinant (synthetic) form of human tissue kallikrein 1 (KLK1). KLK1 is a serine protease (protein) that plays an important role in the regulation of diverse physiological processes including blood flow, inflammation, fibrosis, oxidative stress and neurogenesis via a molecular mechanism that increases production of nitric oxide and prostaglandin. KLK1 deficiency may play a role in multiple vascular and fibrotic diseases such as stroke, chronic kidney disease, retinopathy, vascular dementia, and resistant hypertension where current treatment options are limited or ineffective. DiaMedica is the first company to have developed and clinically studied a recombinant form of the KLK1 protein. The KLK1 protein, produced from the pancreas of pigs and human urine, has been used to treat patients in Japan, China and South Korea for decades. DM199 is currently being studied in patients with acute ischemic stroke (AIS). In September 2021, the FDA granted Fast Track Designation to DM199 for the treatment of AIS.

    About DiaMedica Therapeutics Inc.

    DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. DiaMedica's lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in China for the treatment of acute ischemic stroke and other vascular diseases, to be clinically studied in the United States. For more information visit the Company's website at www.diamedica.com.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and forward-looking information that are based on the beliefs of management and reflect management's current expectations. When used in this press release, the words "anticipates," "believes," "look forward," "continue," "could," "expects," "intends," "may," "plans," "potential," "should," or "will," the negative of these words or such variations thereon or comparable terminology, and the use of future dates are intended to identify forward-looking statements. The forward-looking statements in this press release include statements regarding the anticipated clinical benefits and success of DM199 and the Company's belief that the ReMEDy2 trial has the potential to serve as a pivotal registration study of DM199 in acute ischemic stroke patients. Such statements reflect management's current view and DiaMedica undertakes no obligation to update or revise any of these statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Applicable risks and uncertainties include, among others, DiaMedica's ability to conduct successful clinical testing of DM199 for the treatment of acute ischemic stroke and within its anticipated parameters, enrollment numbers, costs and timeframes, and other risks identified under the heading "Risk Factors" in DiaMedica's annual report on Form 10-K for the fiscal year ended December 31, 2022 and subsequent U.S. Securities and Exchange Commission filings, including DiaMedica's quarterly report on Form 10-Q for the quarterly period ended September 30, 2023. The forward-looking information contained in this press release represents the expectations of DiaMedica as of the date of this press release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While DiaMedica may elect to, it does not undertake to update this information at any particular time except as required in accordance with applicable laws.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240122533463/en/

    Get the next $DMAC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DMAC
    $MRNS
    $NKTR

    CompanyDatePrice TargetRatingAnalyst
    Nektar Therapeutics
    $NKTR
    4/11/2025$2.00Hold → Buy
    Jefferies
    Nektar Therapeutics
    $NKTR
    3/14/2025$6.00Perform → Outperform
    Oppenheimer
    Nektar Therapeutics
    $NKTR
    1/8/2025$4.00Buy
    B. Riley Securities
    Nektar Therapeutics
    $NKTR
    12/10/2024$6.50Buy
    H.C. Wainwright
    Nektar Therapeutics
    $NKTR
    11/4/2024$7.00Overweight
    Piper Sandler
    DiaMedica Therapeutics Inc.
    $DMAC
    10/7/2024$7.00Buy
    H.C. Wainwright
    Nektar Therapeutics
    $NKTR
    9/30/2024$4.00Buy
    BTIG Research
    Marinus Pharmaceuticals Inc.
    $MRNS
    9/23/2024$6.00Perform → Outperform
    Oppenheimer
    More analyst ratings

    $DMAC
    $MRNS
    $NKTR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nektar Therapeutics Reports First Quarter 2025 Financial Results

      SAN FRANCISCO, May 8, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the first quarter ended March 31, 2025. Cash and investments in marketable securities on March 31, 2025 were $220.7 million as compared to $269.1 million on December 31, 2024. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the fourth quarter of 2026. "We are on track to report topline data in June from the Phase 2 study of rezpegaldesleukin in atopic dermatitis," said Howard W. Robin, President a

      5/8/25 4:15:00 PM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May

      DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company will participate in upcoming investor conferences in May 2025. 2025 RBC Capital Markets Global Healthcare Conference Tuesday, May 20th – Wednesday, May 21st, 2025, in New York City, New York. Management will be available for one-on-one meetings throughout the conference. H.C. Wainwright 3rd Annual BioConnect Conference Tuesday, May 20th, 2025, in New York City, New York. Management will participate in a fireside chat at 3:30 PM ET, which will be available via webcast at https://journey.ct.events/view/cb8

      5/8/25 4:00:00 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025

      DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its first quarter 2025 financial results will be released after the markets close on Tuesday, May 13th. DiaMedica will host a live conference call on Wednesday, May 14th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Wednesday, May 14, 2025 Time: 8:00 AM ET / 7:00 AM CT Web access: https://app.webinar.net/24NpV0mjklG Dial In: (800) 836-8184 Conference ID: 93262 Interested parties may access the

      5/7/25 8:30:00 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    $MRNS
    $NKTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Nektar Therapeutics upgraded by Jefferies with a new price target

      Jefferies upgraded Nektar Therapeutics from Hold to Buy and set a new price target of $2.00

      4/11/25 8:15:16 AM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nektar Therapeutics upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Nektar Therapeutics from Perform to Outperform and set a new price target of $6.00

      3/14/25 7:38:49 AM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities initiated coverage on Nektar Therapeutics with a new price target

      B. Riley Securities initiated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $4.00

      1/8/25 8:04:14 AM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    $MRNS
    $NKTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Marinus Pharmaceuticals Inc.

      SC 13G/A - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

      11/15/24 10:35:20 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Marinus Pharmaceuticals Inc.

      SC 13G - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

      11/14/24 6:39:04 PM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Marinus Pharmaceuticals Inc.

      SC 13G/A - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

      11/14/24 3:04:48 PM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    $MRNS
    $NKTR
    Financials

    Live finance-specific insights

    See more
    • Nektar Therapeutics Reports First Quarter 2025 Financial Results

      SAN FRANCISCO, May 8, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the first quarter ended March 31, 2025. Cash and investments in marketable securities on March 31, 2025 were $220.7 million as compared to $269.1 million on December 31, 2024. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the fourth quarter of 2026. "We are on track to report topline data in June from the Phase 2 study of rezpegaldesleukin in atopic dermatitis," said Howard W. Robin, President a

      5/8/25 4:15:00 PM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025

      DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its first quarter 2025 financial results will be released after the markets close on Tuesday, May 13th. DiaMedica will host a live conference call on Wednesday, May 14th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Wednesday, May 14, 2025 Time: 8:00 AM ET / 7:00 AM CT Web access: https://app.webinar.net/24NpV0mjklG Dial In: (800) 836-8184 Conference ID: 93262 Interested parties may access the

      5/7/25 8:30:00 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets

      SAN FRANCISCO, May 1, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 8, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. The web

      5/1/25 6:00:00 PM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    $MRNS
    $NKTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Pilnik Richard D. exercised 24,000 units of Voting Common Shares at a strike of $2.11, increasing direct ownership by 8% to 312,995 units (SEC Form 4)

      4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

      4/8/25 4:41:36 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director O'Connor Daniel J.

      4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

      2/24/25 5:06:33 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider O'Connor Daniel J.

      3 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

      2/24/25 4:54:22 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    $MRNS
    $NKTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHAIRMAN AND CEO Braunstein Scott bought $6,526 worth of shares (5,933 units at $1.10) and returned $167,530 worth of shares to the company (304,600 units at $0.55), closing all direct ownership in the company (SEC Form 4)

      4 - MARINUS PHARMACEUTICALS, INC. (0001267813) (Issuer)

      2/11/25 9:11:48 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Von Koch Thomas bought $3,000,000 worth of shares (1,200,000 units at $2.50) (SEC Form 4)

      4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

      7/1/24 4:27:16 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Stahlberg Jan bought $3,000,000 worth of shares (1,200,000 units at $2.50) (SEC Form 4)

      4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

      7/1/24 4:24:38 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    $MRNS
    $NKTR
    SEC Filings

    See more
    • Nektar Therapeutics filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)

      5/8/25 4:20:26 PM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Nektar Therapeutics

      DEF 14A - NEKTAR THERAPEUTICS (0000906709) (Filer)

      4/25/25 4:15:48 PM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Nektar Therapeutics

      PRE 14A - NEKTAR THERAPEUTICS (0000906709) (Filer)

      4/15/25 4:39:35 PM ET
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    $MRNS
    $NKTR
    Leadership Updates

    Live Leadership Updates

    See more
    • DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors

      DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the election of Daniel J. O'Connor to its Board of Directors, effective February 20, 2025. Mr. O'Connor has decades of executive experience and leadership in the biopharmaceutical industry, including as CEO and other executive level leadership positions at Ambrx Biopharma, Inc. (Ambrx), ImClone Systems Incorporated, Bracco Diagnostics, and PharmaNet (today, Syneos Health). Mr. O'Connor has gained a reputation as a seasoned and successful biopharma CEO, most recently serving as President, Chief Executive Officer and Director of Ambrx, wher

      2/24/25 8:30:00 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

      Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh

      1/22/24 8:23:00 AM ET
      $DMAC
      $MRNS
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer

      Dr. Shah Has Spent Over Two Decades Leading Biological Development Teams at Biotechnology Companies and Has Deep Expertise in Protein Development and Manufacturing DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Ambarish Shah, Ph.D. as Chief Technology Officer. Dr. Shah will lead the development of DiaMedica's manufacturing operations for the late-stage drug candidate DM199. Since May 2023, Dr. Shah has been advising DiaMedica as it worked through the final resolution of the clinical hold on the investigational new drug applic

      9/12/23 8:13:00 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care